A SMART Map for Precision Medicine
The first draft of the SMART Map for Precision Medicine (available on the website) is the outcome of two workshops that took place during the first quarter of 2017, in Aarhus (Denmark) and Valencia (Spain). The Industrial Dialogues brought together actors from industry, civil society and the public sector with the goal to co-design tools that will enable businesses to address questions of social and environmental responsibility they face in their innovation processes.
Francesco Lescai, SMART-map coordinator and Associate Professor in Genomics and Bioinformatics at Aarhus University, provides an overview of the SMART Map that has been elaborated so far.
“The SMART Map that we have drafted for precision medicine is slightly different from what we imagined at the beginning of the project. This is because of the contributions from the participants that have been far more complex and productive than expected. We have to separate two phases: in the first phase we present a set of what we call tool-boxes, tools that embrace the all ecosystems of stakeholders. In the second phase, we select among those, as the timeframe and the resources in the initial design of the pilot will probably not allow to test the complexity of the tools that have been proposed during the Industrial Dialogues.
The SMART Map contains three elements: an element of policy, where we are representing these framework conditions that the participants have put forward very strongly on the table. Then will contain these ecosystem tools, where the participation and the engagement of multiple stakeholders is required to make them work in a real framework. And a third section where we have listed and highlighted a set of tools that we are now going to discuss with companies in precision medicine in order to initiate the next part of the project: the pilot phase.”
Precision Medicine in Europe
“This is a very crucial moment for Europe as well – Lescai explains – because Europe has just formalized the International Consortium for Personalized Medicine (ICPerMed).”
The aim of ICPerMed, a platform that brings together over 30 European and international partners representing ministries, funding agencies and the European Commission (EC), is to boost personalised medicine by an enhanced coordination and alignment of research activities.
Last March the Consortium has released an Action Plan, a blueprint for a coordinated approach for personalised medicine research and the reasonable implementation of innovative and promising approaches in the health systems. As Lescai says, it is very important that this kind of initiatives takes on board RRI elements since the beginning: SMART-map is looking forward to establish a dialogue with members from ICPerMed.